- Advertisement -
Home CURRENT AFFAIRS BUSINESS Stock Market Today: GIFT Nifty indicates a flat start; SBI, Dabur India...

Stock Market Today: GIFT Nifty indicates a flat start; SBI, Dabur India in focus

The NSE IX's GIFT Nifty dropped nine points, or 0.04 percent, to 21,770, suggesting that Dalal Street would probably have a low key week to start.

Stock Market Today

Stock Market Today: GIFT Nifty on the NSE IX fell nine points, or 0.04 percent, to 21,770, indicating that Dalal Street would likely have a quiet start to the week. On the daily chart, the Nifty finished Thursday 141 points higher, forming an Inside Bar candle. The index recovered quickly after two days of bearish trading, indicating that bulls are still in control of the market. Analysts said that the current mood points to a positive trajectory for the Nifty, which is expected to reach 21,800–21,850. With the support of a bullish trend in domestic equities and the US dollar’s weakness in the foreign exchange market, the rupee strengthened 6 paise to close at 83.24 against the US dollar on Thursday.

Stock Market Today: Stocks in focus

Dabur India

Domestic FMCG giant Dabur India stated in a business update that demand trends showed “sequential improvement” in the December quarter, despite the fact that rural growth was still trailing urban growth. Revenue growth in the “mid to high single-digit range during Q3 FY24” is anticipated by the company. In constant currency terms, international business is predicted to grow by double digits, driven primarily by strong momentum in the MENA region.

State Bank of India

The biggest lender in the nation has declared the successful closing of the $250 million senior unsecured Green floating rate notes, also known as “The Green Notes.” This issuance, which has a maturity date of December 29, 2028, was made possible by a private placement arranged by SBI’s London branch and is a part of its $10 billion medium-term note programme. The Green Notes, which have an S&P rating of BBB-, were listed on the India International Exchange and were issued with a floating rate of 1.20% above SOFR.

Lupin

The US FDA has tentatively approved the pharmaceutical giant’s shortened new drug application for 5 mg/5 mg and 10 mg/5 mg strengths of Saxagliptin and Dapagliflozin tablets. For adults with type 2 diabetes, dapagliflozin and saxagliptin tablets are recommended as supplements to diet and exercise in order to improve glycemic control.

Disclaimer: (This information is provided solely for informational purposes. It is important to note that investing in the market or a business idea involves market risks. Before investing money as an investor/ owner/ partner, always consult an expert. DNP News Network Private Limited never advises to invest money on stocks or any specific business idea. We will not be liable for any financial losses.)

Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOKINSTAGRAM, and TWITTER

- Advertisement -
Exit mobile version